DongYing Pharmaceutical

SPH Dongying (Jiangsu) Pharmaceutical, a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., is a specialty pharmaceutical company based in Nantong, China, focused on anesthesia-assisted agents and critical care medications. The company is a leading producer of cisatracurium besylate (marketed as Kutai), a neuromuscular blocking agent that holds a significant share of the Chinese anesthesia market. Originally established as Nantong Dongying Pharmaceutical and formerly part of the US-listed Sinobiopharma, the company was integrated into the Shanghai Pharma group to leverage its expertise in freeze-dried formulation technology. Its portfolio also includes anti-infectives such as clindamycin and a pipeline of novel agents like esaconazole sulfate. SPH Dongying operates GMP-certified manufacturing facilities and is a key player in the domestic supply of essential surgical medications.